Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism

European Journal of Endocrinology

Volumn 154, Issue 1, 2006, Pages 93-99

  Kobayashi, Keisuke ^b   Imanishi, Yasuo ^b   Miyauchi, Akimitsu ^a   Onoda, Naoyoshi ^b   Kawata, Takehisa ^b   Tahara, Hideki ^b   Goto, Hitoshi ^b   Miki, Takami ^b   Ishimura, Eiji ^b   Sugimoto, Toshitsugu ^c   Ishikawa, Tetsuro ^b   Inaba, Masaaki ^b   Nishizawa, Yoshiki ^b  

^a Japan   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CREATININE; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D DERIVATIVE; VITAMIN D;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PARATHYROID GLAND; PARATHYROIDECTOMY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CALCIUM METABOLISM; CLINICAL ARTICLE; HORMONE ACTION; HUMAN TISSUE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PROTEIN ANALYSIS; PROTEIN SYNTHESIS REGULATION;

CALCIUM; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MIDDLE AGED; PARATHYROID GLANDS; PARATHYROIDECTOMY; PHOSPHATES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 32844468124     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02053     Document Type: Article

References (12)

1. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J & Juppner H. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. New England Journal of Medicine 2003 348 1656-1663.
2. White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljunggren O, Meitinger T, Strom TM, Juppner H & Econs MJ. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. Journal of Clinical Endocrinology and Metabolism 2001 86 497-500.
3. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T & Fukumoto S. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. Journal of Clinical Endocrinology and Metabolism 2002 87 4957-4960.
4. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nature Genetics 2000 26 345-348.
5. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM & Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney International 2001 60 2079-2086.
6. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S & Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. PNAS 2001 98 6500-6505.
7. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E & Nishizawa Y. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney International 2004 65 1943-1946.
8. Larsson T, Nisbeth U, Ljunggren O, Juppner H & Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney International 2003 64 2272-2279.
9. Singh RJ & Kumar R. Fibroblast growth factor 23 concentrations in Immoral hypercalcemia of malignancy and hyperparathyroidism. Mayo Clinical Proceedings 2003 78 826-829.
10. Yamashita H, Yamashita T, Miyamoto M, Shigematsu T, Kazama JJ, Shimada T, Yamazaki Y, Fukumoto S, Fukagaw M & Noguchi S. Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. European Journal of Endocrinology 2004 151 55-60.
11. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K & Fukushima N. Circulating FGF-23 is regulated by 1alpha, 25-dihydroxyvitamin D3 and phosphorus in vivo. Journal of Biological Chemistry 2005 280 2543-2549.
12. Tebben PJ, Singh RJ, Clarke BL & Kumar R. Fibroblast growth factor 23, parathyroid hormone, and 1alpha, 25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clinical Proceedings 2004 79 1508-1513.